学术探索
学术期刊
新闻热点
数据分析
智能评审

Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis

被引：31
作者：
Manosuthi, Weerawat
Ruxrungtham, Kiat
Likanonsakul, Sirirat
Prasithsirikul, Wisit
Inthong, Yaowarat
Phoorisri, Thanongsri
Sungkanuparph, Somnuek
机构：
[1] Bamrasnaradura Infect Dis Inst, Minist Publ Hlth, Dept Med, Nonthaburi 11000, Thailand
[2] Mahidol Univ, Ramathibodi Hosp, Fac Med, Bangkok 10400, Thailand
[3] Chulalongkorn Univ, Bangkok, Thailand
[4] Thai Red Cross AIDS Res Ctr, HIV Netherlands Australia Thailand Res Collaborat, Bangkok, Thailand
来源：
CLINICAL INFECTIOUS DISEASES | 2007年 / 44卷 / 01期
关键词：
D O I：
10.1086/510078
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Seventy patients with human immunodeficiency virus (HIV) and tuberculosis coinfection who initiated nevirapine-based antiretroviral therapy and had trough nevirapine levels determined while receiving rifampicin were enrolled in a study. After discontinuation of rifampicin therapy, mean nevirapine levels (+/- standard deviation) increased from 5.4 +/- 3.5mg/L to 6.4 +/- 3.4mg/ L (P = .047), but no nevirapine-related adverse events occurred. There was no statistically significant difference in 60-week antiviral efficacy between these patients and patients receiving nevirapine-based antiretroviral therapy alone (P >.05).
引用
收藏
页码：141 / 144
页数：4
相关论文
共 15 条
[1]   Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs [J].
Ananworanich, J ;
Moor, Z ;
Siangphoe, U ;
Chan, J ;
Cardiello, P ;
Duncombe, C ;
Phanuphak, P ;
Ruxrungtham, K ;
Lange, J ;
Cooper, DA .
AIDS, 2005, 19 (02) :185-192
[2]  
Autar RS, 2005, ANTIVIR THER, V10, P937
[3]   Pharmacokinetic drug interactions with nevirapine [J].
Back, D ;
Gibbons, S ;
Khoo, S .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 :S8-S14
[4]   Sex differences in nevirapine rash [J].
Bersoff-Matcha, SJ ;
Miller, WC ;
Aberg, JA ;
van der Horst, C ;
Hamrick, HJ ;
Powderly, WG ;
Mundy, LM .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (01) :124-129
[5]  
de Requena DG, 2002, AIDS, V16, P290, DOI 10.1097/00002030-200201250-00020
[6]   Effect of tuberculosis therapy on nevirapine trough plasma concentrations [J].
Dean, GL ;
Back, DJ ;
de Ruiter, A .
AIDS, 1999, 13 (17) :2489-2490
[7]   HIGH-DOSE NEVIRAPINE - SAFETY, PHARMACOKINETICS, AND ANTIVIRAL EFFECT IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
HAVLIR, D ;
CHEESEMAN, SH ;
MCLAUGHLIN, M ;
MURPHY, R ;
ERICE, A ;
SPECTOR, SA ;
GREENOUGH, TC ;
SULLIVAN, JL ;
HALL, D ;
MYERS, M ;
LAMSON, M ;
RICHMAN, DD .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (03) :537-545
[8]  
Kappelhoff BS, 2005, ANTIVIR THER, V10, P145
[9]   Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy [J].
Manosuthi, Weerawat ;
Chottanapand, Suthat ;
Thongyen, Supeda ;
Chaovavanich, Achara ;
Sungkanuparph, Somnuek .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (01) :42-46
[10]   Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin [J].
Manosuthi, Weerawat ;
Sungkanuparph, Somnuek ;
Thakkinstian, Ammarin ;
Rattanasiri, Sasivimol ;
Chaovavanich, Achara ;
Prasithsirikul, Wisit ;
Likanonsakul, Sirirat ;
Ruxrungtham, Kiat .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (02) :253-255
12